Building Blocks Catalog

284 Thousand compounds in stock

Original and unique

Make-on-demand
Building Blocks

210 Million novel building blocks

Reliable supply

Custom Synthesis

Over 650 highly skillful chemists

Unique synthesis technologies

Library Synthesis

36B Billion REAL compounds and

Custom Library Synthesis

FTE Chemistry Support

On site access to all Enamine stock BB’s

Highly flexible arrangements

2 000 new building blocks are synthesized monthly. Here is an important update to our MedChem Highlights from May 2023

Recent News

  • 22 May 2023   Press Releases

    Enamine Launches a New Chemistry Site in Germany

    Welcome to the latest update from Enamine - we're delighted to share our growth story with you. In our continued pursuit of scientific excellence and global expansion, we've launched a new subsidiary, Enamine Germany GmbH, based in Frankfurt's Höchst Industrial Park. This significant development strengthens our commitment to provide more localized and efficient services in organic synthesis and medicinal chemistry.

  • 27 April 2023   Press Releases

    Nostrum Biodiscovery and ENAMINE Join Forces to Develop a ...

    Barcelona, Spain, and Kyiv, Ukraine, April 27, 2023. Nostrum Biodiscovery, a leading provider of computational drug discovery services, and ENAMINE, a global supplier of chemical building blocks and screening compounds, announced today a groundbreaking collaboration for the co-development of a revolutionary search engine tailored for the REAL Space billion database. This partnership aims to deliver unparalleled performance in searching vast chemical spaces while utilizing low computational resources, thus increasing the efficiency and accessibility of drug discovery efforts.

    The collaboration will also focus on enhancing High Throughput Virtual Screening (HTVS) services to streamline the drug discovery process. Nostrum Biodiscovery's state-of-the-art AI-enabled screening platform will take center stage in this effort, boasting the capability to evaluate the entire billion compound collection in just hours. This innovative technology promises to identify potential drug candidates within weeks, significantly accelerating the discovery pipeline.

    ENAMINE’s expertise in the rapid and reliable provision of compounds will further strengthen the collaboration, ensuring that researchers have timely access to the vast array of molecules in the REAL Space database. This partnership will facilitate the seamless integration of Nostrum Biodiscovery's computational prowess with ENAMINE’s extensive compound collection, directly impacting companies interested in using services offered by both partners and ultimately benefiting the global scientific community and accelerating the path to new drug discoveries.

    [Victor Guallar, CSO Nostrum Biodiscovery] “We see it every day in our projects, using the REAL Space database with our AI/MM hybrid HTVS platform is a game changer in finding molecules. Our joint venture with ENAMINE demonstrates our commitment to integrating cutting-edge technology and high-quality compound collections to provide the pharmaceutical industry with unparalleled access to resources that expedite drug discovery. We believe that this partnership will serve as a catalyst for innovation, inspiring ventures to explore uncharted territories in the quest for novel therapeutics.”

    [Andrey Tarnovskiy, Sales Director, Europe at Enamine] “This year the size of Enamine’s REAL Space has reached tremendous 36 Billion compounds. We are excited to cooperate with Nostrum Biodiscovery to complement the available suite of search tools for REAL Space exploration with brand-new AI-based solution for high-throughput virtual screening and hope that our synergy will allow to facilitate and strengthen the drug discovery efforts of our customers.”

    Read Press Release

  • 19 April 2023   Press Releases

    Enamine and Endogena Therapeutics – a Successful, Multi-Year Drug ...

    Kyiv, Ukraine, April 19, 2023 - Enamine Ltd., a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments, and screening compounds, gave an update of its long-standing research collaboration with Endogena Therapeutics AG, a clinicalstage biotech company focused on the development of endogenous regenerative medicines.

    Enamine provides Endogena with its integrated capability in medicinal chemistry to support Endogena’s small molecule drug discovery programs in the fields of hit finding, hit-to-lead and lead optimization.

    The companies have been collaborating under a Full Time Equivalent (FTE) model since 2019. The two discovery partners have been continuing their research collaboration to date, their research relationship not being impacted by the war in Ukraine. This collaboration extension, along with many others and new ones established by Enamine since February 24, 2022, already under the conflict, is a systematic positive trend experienced by the company, that demonstrates the support of its customers and the trust they have in receiving high-quality service backed up by the unparalleled number of diverse building blocks available at Enamine.

    Sven Weiler, Vice President of Medicinal Chemistry at Endogena, commented: “The interaction with colleagues from Enamine has been a smooth one from the start. In addition to the FTE model, it is great to have access to their huge compound collection and be able to flexibly use Enamine’s capacity to its full potential. We value the output and responsiveness of the Enamine team, helping us to achieve our demanding milestones. It is stunning to see how well Enamine has been able to keep pace after February 2022.”

    Michael Bossert, Head of Strategic Alliances at Enamine, added: “After 13 months of the war in the country, we are especially pleased to announce our collaboration with Endogena, a longlasting partner we have been serving during those several years with extensive medicinal chemistry and SAR efforts”.

    Read Press Release

Upcoming events

  • Jun 18-22

    Sponsoring

    International Summer School on Organic Synthesis "A. Corbella" - ISOS 2023

  • Jun 18-22

    Delegation

  • Jun 1-2

    Sponsoring

    Journées ChemBioFrance de la Chimiothèque Nationale

Dear Colleagues, Customers, and Friends,

It has been 43 days.

Forty-three days with thousands of bombs, shells, and missiles fired out at our cities and villages, thousands of destroyed buildings, bridges, streets, thousands of killed people. And there are to be feared thousands of victims yet to come as the war continues with a new focus to the East of our country, the war for democracy to prevail against dictatorship and tyranny, the war of the civilized world against the paranoiac barbarians, the war of good against evil. Russia commits genocide against Ukrainians, terrorizes the population, and engages in looting. Nowadays after the crimes in Chernihiv and Kharkiv, after the massacre in Bucha, Irpin and Borodyanka, everybody understands: the world appears to be once again black and white these days and one can see clearly who stands on the side of Ukraine.

I am thankful to the countries and businesses that support Ukraine. I thank those of you who provide donations and help our refugees, everyone who decided to stop paying taxes and operation in Russia, and everyone who just spreads the truth and makes others aware of it. It is hard to overestimate the importance of knowing and feeling that we are not alone in our fight for freedom.

EnamineThe situation in Kyiv has significantly improved and normalized for the past 2 weeks, so is the west part of our country. We are glad to see that several countries are re-opening their embassies in Kyiv. The president of the European Commission, Ursula von der Leyen, will visit Kyiv in the coming days. This shows optimal level of safety for our employees notably, and that the city returns to normal life. Following the call of our President and Prime minister to resume operations where and when it is possible, in compliance with strict safety regulations ruled by our local authorities, we, Team Enamine including already over 300 chemists, have collectively decided to get back to work in Kyiv. Indeed, gradually, since not all the chemistry can be performed right now, e.g., we avoid performing large-scale synthesis. We also expect some delays with purification and delivery for the first period, being determined to solve these issues as soon as possible with the drastically improving situation. We confirm that a major part of our synthetic operations can be performed, and that our chemists and biologists are ready and motivated to work on your projects and tasks.

Now I personally address these words to you, our valued customers and supporters. Please kindly consider resuming ordering our products and services and let us just do in that manner what we love and are best at: the synthesis. Please help us to restart the work at our full steam on custom synthesis, FTE projects and synthesis of make-on-demand building blocks. We are delighted to continue working with our established customers and are most happy to start new collaborations as we are solicitated.

Continuing ordering our compounds and services is the best support because it allows us to operate and keep our employees, our business and Ukraine strong, beside the other key reason of expediting uniquely your valuable research programs with the Art of Enamine.

Thank you!

Slava Ukraini!

Andrey Tolmachov
Founder and CEO of Enamine

FOLLOW US